» Articles » PMID: 28317082

Current Review on High-Risk Multiple Myeloma

Overview
Publisher Current Science
Specialties Hematology
Oncology
Date 2017 Mar 21
PMID 28317082
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: New risk stratification systems and treatment strategies have been introduced in recent years. We aim to provide an overview of these recent changes and summarise these data in a concise article that would be useful for clinicians.

Recent Findings: Apart from clinical stage, disease genetics are now recognised as important prognostic risk factors, and various new cytogenetic changes with negative prognostic impact have been identified. New technologies such as minimal residual disease detection are also playing an important role in prognostic assessment. Recent introduction of combination therapy with proteasome inhibitors and immunomodulatory drugs is showing promising results in high-risk patients and may partially abrogate the negative impact associated with some of the adverse risk factors. Recent advance has improved our understanding of high-risk multiple myeloma, and new therapeutic agents are now coming through the pipeline for this patient group with once dismal outcome.

Citing Articles

Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging.

Den Berghe T, Verberckmoes B, Kint N, Wallaert S, De Vos N, Algoet C Insights Imaging. 2024; 15(1):106.

PMID: 38597979 PMC: 11006637. DOI: 10.1186/s13244-024-01672-1.


Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma.

Abramson H Int J Mol Sci. 2023; 24(3).

PMID: 36768967 PMC: 9917049. DOI: 10.3390/ijms24032645.


Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation.

Hu S, Liu M, Zhang J World J Clin Cases. 2022; 10(32):11712-11725.

PMID: 36405288 PMC: 9669873. DOI: 10.12998/wjcc.v10.i32.11712.


Immunotherapy of Multiple Myeloma: Promise and Challenges.

Abramson H Immunotargets Ther. 2021; 10:343-371.

PMID: 34527606 PMC: 8437262. DOI: 10.2147/ITT.S306103.


An interactive nomogram based on clinical and molecular signatures to predict prognosis in multiple myeloma patients.

Liu L, Qu J, Dai Y, Qi T, Teng X, Li G Aging (Albany NY). 2021; 13(14):18442-18463.

PMID: 34260414 PMC: 8351694. DOI: 10.18632/aging.203294.


References
1.
Dhakal B, Vesole D, Hari P . Allogeneic stem cell transplantation for multiple myeloma: is there a future?. Bone Marrow Transplant. 2016; 51(4):492-500. DOI: 10.1038/bmt.2015.325. View

2.
Usmani S, Rodriguez-Otero P, Bhutani M, Mateos M, Miguel J . Defining and treating high-risk multiple myeloma. Leukemia. 2015; 29(11):2119-25. DOI: 10.1038/leu.2015.209. View

3.
Kuiper R, Broyl A, de Knegt Y, van Vliet M, van Beers E, van der Holt B . A gene expression signature for high-risk multiple myeloma. Leukemia. 2012; 26(11):2406-13. DOI: 10.1038/leu.2012.127. View

4.
Keats J, Reiman T, Maxwell C, Taylor B, Larratt L, Mant M . In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2002; 101(4):1520-9. DOI: 10.1182/blood-2002-06-1675. View

5.
Cavo M, Pantani L, Petrucci M, Patriarca F, Zamagni E, Donnarumma D . Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012; 120(1):9-19. DOI: 10.1182/blood-2012-02-408898. View